← Leaderboards
Eric L Smith
Sloan-Kettering Inst Can Research
$2,298,765
Attributed
$2,298,765
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $513.9K · FY2019–25$1M$750K$500K$250K$0
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$2,298,765 · 2
By mechanism
K08$1,271,047 · 1
R01$1,027,718 · 1
Top collaborators
No co-investigators on record.
Most similar at Sloan-Kettering Inst Can Research
Same institution · by research overlap
- Katharine C Hsu$29,362,365
- Emily Smith Tonorezos$3,220,769
- Marco L. Davila$1,583,287
- Charles L Sawyers$34,701,646
- Gabriela Chiosis$23,584,161
Others in their field
Other Emerging Leaders on “Lead”
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Bambra Strokes · Ppd Development Lp$526,656,217
- Tracy L Nolen · Research Triangle Institute$474,487,152
- Chanza Baytop · Westat, Inc.$271,217,917
- Valerie Koch · University Corporation For Atmospheric Res$243,972,016
- Douglas S. Hawkins · Children'S Hosp Of Philadelphia$157,315,120
Research focus
LeadRelapseDoseIn VivoPreventRefractoryChimeric Antigen Receptor T CellsDisease RemissionFutureImmuneMouse ModelMultiple MyelomaCellsChimeric Antigen ReceptorAntigensAdoptive Cell TransfersAntigen TargetingDesignCar T Cell TherapyEngineeringGeneticHematologic NeoplasmsMediatingResponse
Grant awards (7)
Harnessing naturally occurring cell type-specific regulatory elements and normal HSC hematopoiesis to develop cell lineage-controlled CAR expression and continuously renewing CAR NK cells$513,859
R01 · FY2025 · CA · contact PI
Harnessing naturally occurring cell type-specific regulatory elements and normal HSC hematopoiesis to develop cell lineage-controlled CAR expression and continuously renewing CAR NK cells$513,859
R01 · FY2024 · CA · contact PI
Understanding and addressing sub-optimal responses to CAR T cell therapy for Multiple Myeloma$252,737
K08 · FY2023 · CA · contact PI
Understanding and addressing sub-optimal responses to CAR T cell therapy for Multiple Myeloma$252,737
K08 · FY2022 · CA · contact PI
Understanding and addressing sub-optimal responses to CAR T cell therapy for Multiple Myeloma$252,737
K08 · FY2021 · CA · contact PI
Understanding and addressing sub-optimal responses to CAR T cell therapy for Multiple Myeloma$252,737
K08 · FY2020 · CA · contact PI
Understanding and addressing sub-optimal responses to CAR T cell therapy for Multiple Myeloma$260,099
K08 · FY2019 · CA · contact PI